After AstraZeneca admitted the mistake, the Serum Institute said ‘Oxford covid vaccine is safe’

Symbolic picture

new Delhi:

The Serum Institute of India said on Thursday that the COVID-19 vaccine developed by AstraZeneca and Oxford University is safe and effective and that Indian trials are proceeding smoothly following strict adherence to all protocols. AstraZeneca and the University of Oxford acknowledged a manufacturing error, raising questions about the preliminary results of their experimental COVID-19 vaccine.

Also read

The statement came days after the company and the university described the shots as “highly effective”, explaining the mistake. No mention was made as to why some participants did not receive the vaccine as expected in the first two shots. People have been told to be patient and not to panic. “The AstraZeneca-Oxford vaccine is safe and effective. Even the lowest efficacy results are 60–70%, making it a viable vaccine against the virus,” the Serum Institute of India (SII) said in a statement.

Also read: Corona cases in Delhi cross 5.5 lakh, 5475 new patients came in last 24 hours

“There will be slight variations and efficacy in different dosage forms of different age groups,” the statement said. He said, “We should be patient and not panic.” SII is conducting clinical trials of the AstraZeneca-Oxford-COVID-19 vaccine in India.

SII said, “The Indian trial is going smoothly with strict adherence to all the necessary procedures and protocols. So far, there is no concern. However, we are going through the data that is available and if needed further Will make a statement. ”


Earlier this week, AstraZeneca said in an interim analysis of clinical trials of its COVID-19 vaccine in the UK and Brazil that it was 70 percent effective on average, the third to announce promising results to stop the deadly virus. Became a drugmaker.

The company also said that the vaccine, developed with the University of Oxford, showed 90 percent efficacy at one dose when the vaccine was given in half the dose, at least one month after the full dose, while another 62 percent efficacy was observed when the dose was given as two full doses during at least one month.

(This news has not been edited by the NDTV team. It is published directly from the Syndicate feed.)


Source link

Top News